Cargando…

Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis

INTRODUCTION: Psoriatic arthritis (PsA) is a distinctive inflammatory arthritis which may typically develop in a subgroup of individuals suffering from psoriasis. We recently described progranulin autoantibodies (PGRN-Abs) in the sera of patients with different autoimmune diseases including seronega...

Descripción completa

Detalles Bibliográficos
Autores principales: Thurner, Lorenz, Zaks, Marina, Preuss, Klaus-Dieter, Fadle, Natalie, Regitz, Evi, Ong, Mei Fang, Pfreundschuh, Michael, Assmann, Gunter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978758/
https://www.ncbi.nlm.nih.gov/pubmed/24321127
http://dx.doi.org/10.1186/ar4406
_version_ 1782310627462610944
author Thurner, Lorenz
Zaks, Marina
Preuss, Klaus-Dieter
Fadle, Natalie
Regitz, Evi
Ong, Mei Fang
Pfreundschuh, Michael
Assmann, Gunter
author_facet Thurner, Lorenz
Zaks, Marina
Preuss, Klaus-Dieter
Fadle, Natalie
Regitz, Evi
Ong, Mei Fang
Pfreundschuh, Michael
Assmann, Gunter
author_sort Thurner, Lorenz
collection PubMed
description INTRODUCTION: Psoriatic arthritis (PsA) is a distinctive inflammatory arthritis which may typically develop in a subgroup of individuals suffering from psoriasis. We recently described progranulin autoantibodies (PGRN-Abs) in the sera of patients with different autoimmune diseases including seronegative polyarthritis. In the present study we investigated the occurrence of PGRN-Abs in PsA. METHODS: PGRN-Abs were determined in 260 patients with PsA, 100 patients with psoriasis without arthritic manifestations (PsC) and 97 healthy controls using a recently described ELISA. PGRN plasma levels were determined from subgroups by a commercially available ELISA-kit. Possible functional effects of PGRN-antibodies were analysed in vitro by tumour necrosis factor (TNF)-α mediated cytotoxicity assays using WEHI-S and HT1080 cells. RESULTS: PGRN-Abs were detected with relevant titres in 50/260 (19.23%) patients with PsA, but in 0/100 patients with psoriasis without arthritic manifestations (P = 0.0001). All PGRN-Abs belonged to immunoglobulin G (IgG). PGRN-Abs were significantly more frequent in PsA patients with enthesitis or dactylitis. PGRN-Abs were also more frequent in PsA patients receiving treatment with TNF-α-blockers than in patients treated without TNF-α-blockers (20.8% versus 17.4%; P = 0.016). PGRN plasma levels were significantly lower in PGRN-Ab-positive patients with PsA than in healthy controls and patients with psoriasis without arthritic manifestations (P < 0.001), indicating a neutralizing effect of PGRN-Abs. Moreover cytotoxicity assays comparing PGRN-antibody positive with negative sera from matched patients with PsA, clearly showed a proinflammatory effect of PGRN antibodies. CONCLUSION: Neutralizing PGRN-Abs occur with relevant titres in a subgroup of patients with PsA, but not in patients without arthritic manifestations (PsC). PGRN-Ab-positive patients had more frequent enthesitis or dactylitis. TNF-α-induced cytotoxicity assays demonstrated that the protective effects of progranulin were inhibited by serum containing PGRN-Abs. This suggests that PGRN-Ab might not only be useful as a diagnostic and prognostic marker, but may provide a proinflammatory environment in a subgroup of patients with PsA.
format Online
Article
Text
id pubmed-3978758
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39787582014-04-09 Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis Thurner, Lorenz Zaks, Marina Preuss, Klaus-Dieter Fadle, Natalie Regitz, Evi Ong, Mei Fang Pfreundschuh, Michael Assmann, Gunter Arthritis Res Ther Research Article INTRODUCTION: Psoriatic arthritis (PsA) is a distinctive inflammatory arthritis which may typically develop in a subgroup of individuals suffering from psoriasis. We recently described progranulin autoantibodies (PGRN-Abs) in the sera of patients with different autoimmune diseases including seronegative polyarthritis. In the present study we investigated the occurrence of PGRN-Abs in PsA. METHODS: PGRN-Abs were determined in 260 patients with PsA, 100 patients with psoriasis without arthritic manifestations (PsC) and 97 healthy controls using a recently described ELISA. PGRN plasma levels were determined from subgroups by a commercially available ELISA-kit. Possible functional effects of PGRN-antibodies were analysed in vitro by tumour necrosis factor (TNF)-α mediated cytotoxicity assays using WEHI-S and HT1080 cells. RESULTS: PGRN-Abs were detected with relevant titres in 50/260 (19.23%) patients with PsA, but in 0/100 patients with psoriasis without arthritic manifestations (P = 0.0001). All PGRN-Abs belonged to immunoglobulin G (IgG). PGRN-Abs were significantly more frequent in PsA patients with enthesitis or dactylitis. PGRN-Abs were also more frequent in PsA patients receiving treatment with TNF-α-blockers than in patients treated without TNF-α-blockers (20.8% versus 17.4%; P = 0.016). PGRN plasma levels were significantly lower in PGRN-Ab-positive patients with PsA than in healthy controls and patients with psoriasis without arthritic manifestations (P < 0.001), indicating a neutralizing effect of PGRN-Abs. Moreover cytotoxicity assays comparing PGRN-antibody positive with negative sera from matched patients with PsA, clearly showed a proinflammatory effect of PGRN antibodies. CONCLUSION: Neutralizing PGRN-Abs occur with relevant titres in a subgroup of patients with PsA, but not in patients without arthritic manifestations (PsC). PGRN-Ab-positive patients had more frequent enthesitis or dactylitis. TNF-α-induced cytotoxicity assays demonstrated that the protective effects of progranulin were inhibited by serum containing PGRN-Abs. This suggests that PGRN-Ab might not only be useful as a diagnostic and prognostic marker, but may provide a proinflammatory environment in a subgroup of patients with PsA. BioMed Central 2013 2013-12-10 /pmc/articles/PMC3978758/ /pubmed/24321127 http://dx.doi.org/10.1186/ar4406 Text en Copyright © 2013 Thurner et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Thurner, Lorenz
Zaks, Marina
Preuss, Klaus-Dieter
Fadle, Natalie
Regitz, Evi
Ong, Mei Fang
Pfreundschuh, Michael
Assmann, Gunter
Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis
title Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis
title_full Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis
title_fullStr Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis
title_full_unstemmed Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis
title_short Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis
title_sort progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978758/
https://www.ncbi.nlm.nih.gov/pubmed/24321127
http://dx.doi.org/10.1186/ar4406
work_keys_str_mv AT thurnerlorenz progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis
AT zaksmarina progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis
AT preussklausdieter progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis
AT fadlenatalie progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis
AT regitzevi progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis
AT ongmeifang progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis
AT pfreundschuhmichael progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis
AT assmanngunter progranulinantibodiesentertainaproinflammatoryenvironmentinasubgroupofpatientswithpsoriaticarthritis